ContraVir Pharma Takes Off on Positive Results
ContraVir Pharmaceuticals led the bulls early on Tuesday following the release of positive hepatitis B results.
All Work
Chris Lange
BioPharmX Prices Secondary Offering
BioPharmX saw its shares take a sharp downward turn following the announcement of a secondary offering.
Inovio Fails to Impress With HPV Business Update
Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
Conn’s Disappoints on Bottom Line, Names New Chairman
Conn's reported mixed fiscal fourth-quarter financial results before the markets opened on Tuesday.
8 Major Biopharma Events Coming Later in 2016 and in 2017
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
SEC Charges New Jersey Fund Manager in Pre-IPO Fraud
The SEC has announced fraud charges and asset freezes obtained in a case filed against a New Jersey-based fund manager.
Why Merrill Lynch Sees Acadia Rising Another 60%
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee, which is set to review data…
Apricus Bio Top-Line Results Don’t Stand Up to Expectations
Apricus Biosciences announced top-line results from the Phase 2b proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction.
Alder Biopharma Soars on Positive Mid-Stage Trial Results
Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.
Tactile Systems Prepares for IPO
Tactile Systems Technology has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
5 Credit Suisse Focus List Stocks With the Most Upside
In a new research report, Credit Suisse highlighted some companies on its U.S. Focus List that stand to have the most potential price return.
Top 5 Earnings for the Week Ahead
24/7 Wall St. has put together a preview of Micron Technology, Lululemon and some of the other major companies reporting their quarterly results this week.
5 Key Biopharma Movers From Last Week
Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
How the Financial Sector Has Held Back the Dow in 2016
It has taken about three months for the Dow to get back to positive. The push was in fact made by the Dogs of the Dow, but it was stalled for some time by…
Top 4 Medtech Picks From Merrill Lynch
Merrill Lynch has some ideas about how to take advantage of the trends in health care going forward.
Pandora’s New Director Inspires Optimism
Pandora Media has announced that it is expanding the size of its board from nine seats to 10 with the addition of Anthony J. Vinciquerra.
Celator Pharma Prices Secondary Offering
Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Vitae Pharma Prepares for Secondary Offering
Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to $40 million.
What to Expect From GameStop Earnings
GameStop is scheduled to report its fiscal fourth-quarter financial results after the markets close on Thursday.
Portola Pharma Top-Line Results Miss Par for the Course
Portola Pharmaceuticals made waves early on Thursday morning with less than favorable top-line results.